HC Wainwright Reiterates “Buy” Rating for OnKure Therapeutics (NASDAQ:OKUR)

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued on Thursday, Benzinga reports. They presently have a $40.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 132.96% from the company’s previous close.

Other equities analysts have also issued research reports about the company. Lifesci Capital raised OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, October 10th. Oppenheimer started coverage on OnKure Therapeutics in a research note on Thursday, October 10th. They set an “outperform” rating and a $35.00 price target on the stock.

OnKure Therapeutics Stock Performance

Shares of NASDAQ OKUR traded down $1.42 during midday trading on Thursday, hitting $17.17. The company’s stock had a trading volume of 24,811 shares, compared to its average volume of 27,278. OnKure Therapeutics has a 1 year low of $9.80 and a 1 year high of $86.70. The firm has a market cap of $57.35 million, a price-to-earnings ratio of -1.02 and a beta of 0.21.

OnKure Therapeutics Company Profile

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.